Biotie Therapies Corp.

Quick facts

Phase 2 pipeline

• BTT1023 · Immunology
  BTT1023 is a monoclonal antibody that blocks the CC chemokine receptor 2 (CCR2) to reduce inflammatory cell recruitment and immune activation.

Phase 1 pipeline

• BTT-1023
• ELB353

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Biotie Therapies Corp. portfolio CI brief
• Biotie Therapies Corp. pipeline updates RSS